SGLT-2 inhibitor investigator Mikhail Kosiborod, MD, answers questions about patient selection for the class of drugs, now with approval to treat much more than type 2 diabetes.
"In this day and age...I think you would have to look for a reason not to do it, rather than to look for a reason to do it in patients who have kidney disease."
Dr Mikhail Kosiborod is referring above to prescribing a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for a patient with chronic kidney disease seen in primary care. The same could be said about a patient with type 2 diabetes with risk factors for CKD and/or for cardiovascular disease or a patient with heart failure, either with or without T2D.
Kosiborod is world-renowned for his research in diabetes, cardiovascular disease and cardiometabolic and cardiorenal syndromes. He has been a lead investigator for a number of the studies that have revealed the pluripotent properties of the SGLT2 inhibitor class. He discusses here an approach to patient selection for SGLT-2 inhibitor therapy in primary care and the unprecedented opportunities to improve the quality of and extend life for patients.
Mikhail Kosiborod, MD is Professor of Medicine, University of Missouri Kansas City, Vice President, Research, Saint Luke’s Health System, Executive Director, Cardiometabolic Center Alliance, Director, Cardiometabolic Research and Co-director, Haverty Cardiometabolic Center of Excellence, Saint Luke’s Mid America Heart Institute, Kansas City, MO.